Bausch Health Co. Inc. (BHC) Reports In-Line Q2 Revenue, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bausch Health (BHC) Results 'Good', Solta Could Be Valued at $2.5B+ - Cowen
August 3, 2021 10:54 AM EDTCowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC) following results and news it plans to IPO the aesthetics Solta division.
The analyst commented, "BHC reported a good Q2 with revs and earnings essentially in-line; the... More
